Cited by 764Cancer-related Molecular PathwaysMultiple and Secondary Primary CancersBRCA gene mutations in cancer

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Bougeard, Gaëlle, Renaux-Petel, Mariette, Flaman, Jean-Michel, Charbonnier, Camille, Fermey, Pierre, Belotti, Muriel, Gauthier-Villars, Marion, Stoppa-Lyonnet, Dominique, Consolino, Emilie, Brugières, Laurence, Caron, Olivier, Benusiglio, Patrick R., Bressac-de Paillerets, Brigitte, Bonadona, Valérie, Bonaïti-Pellié, Catherine, Tinat, Julie, Baert-Desurmont, Stéphanie, Frebourg, Thierry·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.5728

Open this paper in CoChat — free account

Abstract

Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5728

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Dominant-negative mutations were defined on the basis of the ability of the mutant protein to inhibit the activity of the wild-type p53 protein,(16) as indicated in the International Agency for Research on Cancer TP53 Database.(17)”
Method
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 553

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

Li FP, 1988, Cancer Res, 48, 5358
Nutting C, 2000, Clin Oncol (R Coll Radiol), 12, 300
Spencer SJ, 1999, J Clin Endocrinol Metab, 84, 1110

Sorted by citations

Items 301–400 of 764

Pediatric cancer genetics
Dean, S., & Farmer, M. B. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000543 · Cited by 9
Family cancer history and smoking habit associated with sarcoma in a Japanese population study
Araki, Y., Yamamoto, N., Tanzawa, Y., Higashi, T., Kuchiba, A., Hayashi, K., Takeuchi, A., Miwa, S., Igarashi, K., Endo, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21500-0 · Cited by 9
Management of Women with a Hereditary Predisposition for Breast Cancer
Jatoi, I., & Benson, J. R. (2016) · Future Oncology · doi:10.2217/fon-2016-0186 · Cited by 10
Cancer predisposition syndromes associated with myeloid malignancy
Quinn, E. A., & Nichols, K. E. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.04.003 · Cited by 9
Tumor Syndromes That Include Bone Tumors
Gnoli, M., Ponti, F., & Sangiorgi, L. (2017) · Surgical pathology clinics · doi:10.1016/j.path.2017.04.009 · Cited by 9
Ein Update zum Li-Fraumeni-Syndrom
Dutzmann, C. M., Vogel, J., Kratz, C. P., Pajtler, K. W., Pfister, S. M., & Dörgeloh, B. B. (2019) · Der Pathologe · doi:10.1007/s00292-019-00657-y · Cited by 9
Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome
Peacock, E. G., Grenon, L. M., Batalini, F., & Tung, N. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00279 · Cited by 10
Feedback of extended panel sequencing in 1530 patients referred for suspicion of hereditary predisposition to adult cancers
Cavaillé, M., Uhrhammer, N. A., Privat, M., Ponelle‐Chachuat, F., Gay‐Bellile, M., Lepage, M., Viala, S., Bidet, Y., & Bignon, Y. (2020) · Clinical Genetics · doi:10.1111/cge.13864 · Cited by 9
Inherited Predisposition to Gastric Cancer
Rustgi, S. D., Ching, C. K., & Kastrinos, F. (2021) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2021.03.010 · Cited by 9
Hereditary Gastrointestinal Tumor Syndromes: When Risk Comes with Your Genes
Fernández‐Aceñero, M. J., & del Arco, C. D. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070385 · Cited by 8
Germline DNA Damage Repair Gene Alterations in Patients with Metachronous Breast and Colorectal Cancer
Villacis, R. A. R., Côrtes, L., Basso, T. R., do Canto, L. M., Souza, J. D. S., Aagaard, M. M., Formiga, M. N., Aguiar, S., Achatz, M. I., & Rogatto, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910275 · Cited by 8
Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark
Stoltze, U. K., Skytte, A., Roed, H., Hasle, H., Ejlertsen, B., Hansen, T. V. O., Schmiegelow, K., Gerdes, A., & Wadt, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190050 · Cited by 8
Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review
Irshaid, L., Clark, M. B., Fadare, O., Finberg, K. E., & Parkash, V. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000792 · Cited by 8
Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
Whitaker, J., Nessim, C., Almond, M., & Ford, S. (2023) · Current Oncology · doi:10.3390/curroncol30030211 · Cited by 8
The role of cancer predisposition syndrome in children and adolescents with very rare tumours
Orbach, D. H., Brecht, I. B., Corradini, N., Bouchoucha, Y. X., Roganović, J., Bourdeaut, F., Réguerre, Y., Kuiper, R. P., Paillerets, B. B., Ferrari, A., et al. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100023 · Cited by 8
Germline Predisposition to Myeloid Neoplasms
Obiorah, I. E., Upadhyaya, K., & Calvo, K. R. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.06.004 · Cited by 8
Characterisation of heritable TP53-related cancer syndrome in Sweden—a nationwide study of genotype-phenotype correlations in 90 families
Omran, M., Liu, Y., Sun-Zhang, A., Poluha, A., Stenmark‐Askmalm, M., Persson, F., Hallbeck, A., Rosén, A., Helgadottir, H. T., Tham, E., et al. (2025) · European Journal of Human Genetics · doi:10.1038/s41431-024-01753-1 · Cited by 11
Targeting pediatric adrenocortical carcinoma: Molecular insights and emerging therapeutic strategies
Kuhlen, M., Schmutz, M., Kunstreich, M., Redlich, A., & Claus, R. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102942 · Cited by 9
Familial solitary chondrosarcoma resulting from germline EXT2 mutation
Heddar, A., Fermey, P., Coutant, S., Angot, É., Sabourin, J., Michelin, P., Parodi, N., Charbonnier, F., Vézain, M., Bougeard, G., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22419 · Cited by 8
Self-citation
Epidemiology and Etiology of Childhood ALL
Tulstrup, M., Stoltze, U. K., Schmiegelow, K., & Yang, J. J. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-39708-5_1 · Cited by 8
Gestational choriocarcinoma associated with a germline TP53 mutation
Bréhin, A., Patrier, S., Bougeard, G., Side-Pfennig, G., Gutierrez, F. L., Lamy, A., Colasse, É., Kandel-Aznar, C., Delnatte, C., Vuillemin, E., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-9996-7 · Cited by 8
Self-citation
Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53
Omran, M., Blomqvist, L., Brandberg, Y., Pal, N., Kogner, P., Ståhlbom, A. K., Tham, E., & Bajalica‐Lagercrantz, S. (2020) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-020-0133-5 · Cited by 8
TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
Grill, S., Ramser, J., Hellebrand, H., Pfarr, N., Boxberg, M., Brambs, C., Ditsch, N. C., Meindl, A., Groß, E., Meitinger, T., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05883-x · Cited by 8
Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors
Wu, D., Lei, Y., Liu, Q., Hu, H., Li, H., Xie, L., & Zhou, J. (2021) · Medicine · doi:10.1097/md.0000000000023777 · Cited by 7
Epidemiology and Etiology of Glioblastoma
Coté, D. J., & Ostrom, Q. T. (2021) · Molecular pathology library · doi:10.1007/978-3-030-69170-7_1 · Cited by 8
Radiotherapy for pediatric adrenocortical carcinoma – Review of the literature
Wiegering, V. A., Riedmeier, M., Thompson, L. D. �., Virgone, C., Redlich, A., Kuhlen, M., Gültekin, M., Yalçın, B., Decarolis, B., Härtel, C., et al. (2022) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2022.05.003 · Cited by 9
A common pathway to cancer: Oncogenic mutations abolish p53 oscillations
Xiong, L., & Garfinkel, A. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.06.002 · Cited by 9
TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report
Fair, D. B., Maese, L. D., Chi, Y., Li, M., Hawkins, D. S., Venkatramani, R., Rudzinski, E. R., Parham, D. M., Teot, L. A., Malkin, D. M., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30413 · Cited by 8
Therapeutic Strategies for Gliomas Associated With Cancer Predisposition Syndromes
Lam, K., Kamiya-Matsuoka, C., Slopis, J. M., McCutcheon, I. E., & Majd, N. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00442 · Cited by 8
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient
Guidi, M., Giunti, L., Lucchesi, M., Scoccianti, S., Giglio, S., Favre, C., Oliveri, G., & Sardi, I. (2016) · Future Oncology · doi:10.2217/fon-2016-0236 · Cited by 8
A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families
Llovet, P., Illana, F. J., Martín-Morales, L., de la Hoya, M., Garré, P., Ibañez-Royo, M. D., Pérez‐Segura, P., Caldés, T., & García‐Barberán, V. (2017) · Familial Cancer · doi:10.1007/s10689-017-9990-0 · Cited by 8
Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine
Powers, B. D., Pal, T., & Laronga, C. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.003 · Cited by 8
Translating genomic risk into an early detection strategy for sarcoma
Ballinger, M. L., Pinese, M., & Thomas, D. M. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22697 · Cited by 8
Li‐Fraumeni syndrome presenting as cutaneous melanoma in a child: case report and review of literature
Baek, Y. S., Seo, J., Song, J. Y., Lee, S. ‐., Kim, A., & Jeon, J.-W. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15430 · Cited by 8
Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status
Brenna, C. T. A., Michaeli, O., Wasserman, J. D., & Malkin, D. M. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001982 · Cited by 8
Genetic Factors
Walsh, M. F., Cadoo, K. A., Salo‐Mullen, E. E., Dubard-Gault, M. E., Stadler, Z. K., & Offit, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00013-x · Cited by 10
Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome
Woodward, E. R., Kilday, J., Ng, S., Kelsey, A. M., & Evans, D. G. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf057 · Cited by 7
Proposed framework for triage of putative germline variants detected via tumour genomic testing in UK oncology practice
McVeigh, T. P., Hanson, H., Burghel, G. J., Turnbull, C., & Snape, K. M. G. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2025-110947 · Cited by 9
Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications
Krückel, A., Gocke, J., Hörner, M., Keller, K., Müller, C., Brückner, L. M., Heindl, F., Hack, C. C., Beckmann, M. W., & Amann, N. (2026) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08270-6 · Cited by 7
Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study
Omran, M., Johansson, H., Lundgren, C., Silander, G., Stenmark‐Askmalm, M., Loman, N., Baan, A., Adra, J., Kuchinskaya, E., Blomqvist, L., et al. (2023) · Cancer · doi:10.1002/cncr.34631 · Cited by 7
The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer
Escudeiro, C., Pinto, C., Vieira, J., Peixoto, A., Pinto, P., Pinheiro, M., Santos, C., Guerra, J., Lisboa, S., Santos, R. P., et al. (2020) · Familial Cancer · doi:10.1007/s10689-020-00212-2 · Cited by 7
Comparison of the fertility of tumor suppressor gene-deficient C57BL/6 mouse strains reveals stable reproductive aging and novel pleiotropic gene
Kohzaki, M., Ootsuyama, A., Umata, T., & Okazaki, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-91342-9 · Cited by 6
Association between Predicted Effects of TP53 Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer
Liu, Y., Axell, O., van Leeuwen, T., Konrat, R., Kharaziha, P., Larsson, C., Wright, A. P. H., & Bajalica‐Lagercrantz, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126345 · Cited by 7
Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil
Bittar, C. M., Rocha, Y. M. D. A., Vieira, I. A., Rosset, C., Andreis, T. F., Sartor, I. T. S., Artigalás, O., Netto, C. B. O., Alemar, B., Macedo, G. S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251639 · Cited by 7
Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients
Siraj, A. K., Masoodi, T., Bu, R., Parvathareddy, S. K., Iqbal, K., Azam, S., Al-Rasheed, M. M., Ajarim, D. S., Tulbah, A. M., Al‐Dayel, F., et al. (2021) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-021-00206-w · Cited by 7
Spectrum and Incidence of Skin Cancer among Individuals with Li-Fraumeni Syndrome
Hatton, J. N., Sargen, M. R., Frone, M. N., de Andrade, K. C., Savage, S. A., & Khincha, P. P. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.02.004 · Cited by 7
Germline predisposition to soft tissue sarcoma
Vagher, J., Dietz, M. S., Schiffman, J. D., Kohlmann, W. K., & Maese, L. D. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.31 · Cited by 7
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation
Yamazaki, F., Shima, H., Osumi, T., Narumi, S., Kuroda, T., & Shimada, H. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000948 · Cited by 7
Atypical cutaneous melanocytic tumours arising in two patients with Li–Fraumeni syndrome
Jacquemus, J., Perron, É., Pissaloux, D., Alberti, L., & de la Fouchardière, A. (2017) · Pathology · doi:10.1016/j.pathol.2017.08.013 · Cited by 7
Premalignant Conditions of Bone
Eckhoff, M. D., Wells, M. E., Padilla, O., Polfer, E. M., Castagno, C. J., Thabet, A. M., Elzamly, S., Wilson, H. L., & Rajani, R. (2022) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-22-00097 · Cited by 7
Identification and Management of TP53 Gene Carriers Detected Through Multigene Panel Testing
Pal, T., Brzosowicz, J., Valladares, A., Wiesner, G. L., & Laronga, C. (2017) · Southern Medical Journal · doi:10.14423/smj.0000000000000711 · Cited by 7
Integrated analysis of cell-free DNA for the early detection of cancer in people with Li-Fraumeni SyndromePreprint
Wong, D., Luo, P., Oldfield, L. E., Gong, H., Brunga, L., Rabinowicz, R., Subasri, V., Chan, C. F., Downs, T., Farncombe, K. M., et al. (2022) · medRxiv · doi:10.1101/2022.10.07.22280848 · Cited by 7
DNA mismatch repair deficiency as a biomarker in sarcoma
Denu, R. A., Quintana-Perez, C. D., Wangsiricharoen, S., Ingram, D. R., Wani, K., Lazar, A. J., Ratan, R., Roland, C. L., & You, Y. N. (2024) · Surgical Oncology Insight · doi:10.1016/j.soi.2024.100091 · Cited by 7
Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome
Freyçon, C., Palma, L., Budd, C., Coulombe, F., Witkowski, L., Hainaut, P. L., Foulkes, W. D., & Goudie, C. (2024) · Familial Cancer · doi:10.1007/s10689-024-00419-7 · Cited by 6
Adrenocortical tumors and hereditary syndromes
Jeyaraman, K., Concolino, P., & Falhammar, H. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2431748 · Cited by 6
A systematic review of high-grade glioma associated with Li-Fraumeni syndrome
Kite, T. S., Yadlapalli, V., Verma, R., Porwal, M. H., Herbst, J., Karlovits, S., Wegner, R. E., & Shepard, M. J. (2025) · Neurosurgical Review · doi:10.1007/s10143-025-03437-w · Cited by 6
Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data
Nguyen, N. H., Dodd-Eaton, E. B., Corredor, J. L., Woodman-Ross, J., Green, S. O., Gutierrez‐Barrera, A. M., Arun, B., & Wang, W. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01926 · Cited by 6
Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia
Yamaguchi, H. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03837-6 · Cited by 7
Prostate cancer and genetic contributions
Chou, W. H., Chalker, C., Sokolova, A. O., & Isharwal, S. (2024) · Andrology · doi:10.1111/andr.13812 · Cited by 6
Cancer risk in carriers of TP53 germline variants grouped into different functional categories
Müntnich, L. J., Dutzmann, C. M., Großhennig, A., Härter, V., Keymling, M., Mastronuzzi, A., Montellier, E., Nees, J., Palmaers, N. E., Penkert, J., et al. (2025) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf008 · Cited by 6
Transmission ratio distortion of germline TP53 variants in Li–Fraumeni syndrome families
Halpern, N., Kventsel, I., Strauss, G. Z., Peerless, Y., Boursi, B., Yalon, M., Goldberg, Y., Kedar, I., Shani, H., Friedman, E., et al. (2025) · Cancer · doi:10.1002/cncr.35943 · Cited by 5
Seltene Tumoren als Leitsymptom hereditärer Tumorsyndrome
Perne, C., Steinke‐Lange, V., Aretz, S., & Spier, I. (2020) · Der Pathologe · doi:10.1007/s00292-020-00806-8 · Cited by 6
The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation
Li, X., Xue, H., Luo, N., Han, T., Li, M., & Jia, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.718689 · Cited by 6
Li–Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype–phenotype correlation
Sassi, H., Meddeb, R., Chérif, M., Nasr, C., Riahi, A., Hannachi, S., Belguith, N., & Mrad, R. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01189-w · Cited by 6
Li-Fraumeni-Syndrom
Keymling, M., Schlemmer, H., Kratz, C. P., Pfeil, A., Bickelhaupt, S., Alsady, T. M., & Renz, D. M. (2022) · Die Radiologie · doi:10.1007/s00117-022-01071-x · Cited by 6
Malignant perivascular epithelioid cell tumor (pecoma) of the uterus as part of the hereditary cancer syndrome: a case diagnosed with multiple malignancies
Çalışkan, S., Akar, Ö. S., Gün, S., & Kefeli, M. (2022) · Turkish Journal of Pathology · doi:10.5146/tjpath.2022.01592 · Cited by 6
Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors
van de Beek, I., Glykofridis, I. E., Wagner, A., den Toom, D. T., Bongers, E. M. H. F., van Leenders, G. J. L. H., Johannesma, P. C., Meijers-Heijboer, H. E. J., Wolthuis, R. M. F., Steensel, M. A. M. V., et al. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2098 · Cited by 6
Integrated gene network analysis sheds light on understanding the progression of Osteosarcoma
Dey, H., Vasudevan, K., Doss, C. G. P., Kumar, S. U., Allali, A. E., Alsamman, A. M., & Zayed, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1154417 · Cited by 7
Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes
Hebert, R., Cullinan, N. M., Armstrong, L., Blood, K. A., Brossard, J., Brunga, L., Cacciotti, C., Caswell, K., Cellot, S., Coltin, H., et al. (2023) · Journal of Medical Genetics · doi:10.1136/jmg-2023-109376 · Cited by 6
CHEK2 is not a Li-Fraumeni syndrome gene: time to update public resources
Fortuño, C., Richardson, M. E., Pesaran, T. F., Yussuf, A., Horton, C., James, P. A., & Spurdle, A. B. (2023) · Journal of Medical Genetics · doi:10.1136/jmg-2023-109464 · Cited by 6
Epithelioid angiomyolipoma of the liver in a patient with Li-Fraumeni syndrome: a case report
Yang, Y., Lee, J., Woo, C. G., Lee, O.-J., & Son, S.-M. (2024) · Diagnostic Pathology · doi:10.1186/s13000-023-01418-5 · Cited by 6
Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse
Waha, A., Versmold, B., Kast, K., Kiechle, M. B., Ditsch, N. C., Meindl, A., Niederacher, D., Hahnen, E., Arnold, N., Mundhenke, C., et al. (2018) · TumorDiagnostik & Therapie · doi:10.1055/a-0574-4879 · Cited by 6
Advances in the Diagnosis and Management of Neonatal Sarcomas
Rashid, T., Noyd, D. H., Iranzad, N., Davis, J. T., & Deel, M. D. (2021) · Clinics in Perinatology · doi:10.1016/j.clp.2020.11.007 · Cited by 6
Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review
Tadros, S., Kondrashov, A., Namagiri, S., Chowdhury, A. K., Banasavadi‐Siddegowda, Y., & Ray‐Chaudhury, A. (2021) · Neurosurgery · doi:10.1093/neuros/nyab019 · Cited by 7
Cancer predisposition genes in Japanese children with rhabdomyosarcoma
Fukushima, H., Suzuki, R., Yamaki, Y., Hosaka, S., Inaba, M., Morii, W., Noguchi, E., & Takada, H. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00961-7 · Cited by 6
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfría, M., Jiménez, I. D. J., Tena, I., Chirivella, I., Richart-Aznar, P., Segura, Á., Sánchez‐Heras, A. B., & Martínez-Dueñas, E. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060548 · Cited by 6
Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients
Tian, P., Zhang, X., Yang, S., Fang, Y., Yuan, H., Li, W., Zhu, H., Zhao, F., Ding, J., Zhu, Y., et al. (2022) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.12.012 · Cited by 6
p53 Tumor Suppressor: Functional Regulation and Role in Gene Therapy
Farooq, Z., Wani, S., Ragunathrao, V. A. B., Kochhar, R. K., & Anwar, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105029 · Cited by 7
Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
Rectal leiomyosarcoma as the initial phenotypic manifestation of Li–Fraumeni-like syndrome: a case report and review of the literature
Severino, N. P., Waisberg, J., Fragoso, M. C. B. V., de Lima, L. G. C. A., Balsamo, F., Henriques, A. C., Bianco, B. A. V., & Gehrke, F. D. S. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03671-6 · Cited by 5
p53 Deficiency-Dependent Oncogenicity of Runx3
Ito, K., Otani, S., & Date, Y. (2023) · Cells · doi:10.3390/cells12081122 · Cited by 6
PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement
Choi, J. I., Wojcieszynski, A. P., Amos, R. A., Giap, H., Apisarnthanarax, S., Ashman, J. B., Anand, A., Perles, L. A., Williamson, T. D., Shanmugasundaram, R., et al. (2024) · International Journal of Particle Therapy · doi:10.1016/j.ijpt.2024.100019 · Cited by 5
Nrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma
Peng, X., Feng, J., Yang, H., Xia, P., & Pu, F. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101335 · Cited by 6
Comprehensive multiomics analysis reveals distinct differences between pediatric choroid plexus papilloma and carcinoma
Choi, Y., Choi, S. A., Koh, E. J., Yun, I., Park, S. H., Jeon, S., Kim, Y., Park, S., Woo, D., Phi, J. H., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01814-y · Cited by 5
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2
Fabi, A., Cortesi, L., Duranti, S., Cordisco, E. L., Leone, A. D., Terribile, D. A., Paris, I., de Belvis, A. G., Orlandi, A., Marazzi, F., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104431 · Cited by 5
Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors
Rosenberger, L. H., Thomas, S. M., Hieken, T. J., Gallagher, K. K., Spanheimer, P. M., Neuman, H. B., Weiss, A. C., King, T. A., Wong, J., Tong, B., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07488-3 · Cited by 5
The spectrum of hematologic neoplasms in patients with Li‐Fraumeni syndrome
Dimopoulos, Y. P., Wang, W., Wang, S. A., Loghavi, S., Dinardo, C. D., Gerstein, Y. S., Hu, S., Tang, Z., Ilagan, C., Thakral, B., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27497 · Cited by 5
Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma
Chen, Y., Fang, S., Zhong, C., Mo, S., Shi, Y., Ling, X., Liu, F., Zhong, W., Deng, J., Dong, Z., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2397092 · Cited by 6
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia
Stoltze, U. K., Junk, S. V., Byrjalsen, A., Cavé, H., Cazzaniga, G., Elitzur, S., Froňková, E., Hjalgrim, L. L., Kuiper, R. P., Lundgren, L., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02535-4 · Cited by 5
Epidermal Growth Factor Receptor-mutated Lung Cancer as the Initial Manifestation of Germline TP53 Mutation Associated Cancer
Pathak, S., Singh, S. R. K., Katiyar, V., & McDunn, S. H. (2018) · Cureus · doi:10.7759/cureus.2395 · Cited by 5
Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center’s 20 years of Experience
Arnon, J., Grozinsky‐Glasberg, S., Oleinikov, K., Gross, D. J., Salmon, A. Y., Meirovitz, A., & Maimon, O. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac112 · Cited by 5
Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study
Yang, L., Xie, F., Liu, C., Zhao, J. X., Hu, T., Wu, J., Zhao, X. T., & Wang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911266 · Cited by 5
Hereditary Conditions Associated with Elevated Cancer Risk in Childhood
Suspitsin, E. N., & Имянитов, Е. Н. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923070039 · Cited by 5
Li-Fraumeni syndrome presenting with de novo TP53 mutation, severe phenotype and advanced paternal age: a case report
Arango-Ibañez, J. P., Parra‐Lara, L. G., Zambrano, A. R., & Rodríguez‐Rojas, L. X. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-023-00272-2 · Cited by 5
Whole-Body MRI Screening for Carriers of Germline TP53 Mutations—A Systematic Review and Meta-Analysis
Temperley, H. C., O’Sullivan, N. J., Curtain, B. M. M., Qian, W., Temperley, T. S., Murray, A., Corr, A., Brennan, I. M., Gallagher, D. J., Meaney, J. F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051223 · Cited by 5
Myc upregulates Ggct, γ‐glutamylcyclotransferase to promote development of p53‐deficient osteosarcoma
Ueno, T., Otani, S., Date, Y., Katsuma, Y., Nagayoshi, Y., Ito, T., Ii, H., Kageyama, S., Nakata, S., & Ito, K. (2024) · Cancer Science · doi:10.1111/cas.16255 · Cited by 4
Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
Maoz, M., Devir, M., Inbar, M., Inbar-Daniel, Z., Sherill-Rofe, D., Bloch, I., Meir, K. S., Edelman, D., Salah, A., Nechushtan, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55455-6 · Cited by 7
Pediatric Head and Neck Tumors Associated with Li-Fraumeni Syndrome
Rodriguez, K. D., Schneider, K. W., Suttman, A., Garrington, T. P., Jellins, T., Tholen, K., Francom, C. R., & Herrmann, B. W. (2021) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894211014786 · Cited by 5
Case Report: Identification of a Novel Pathogenic Germline TP53 Variant in a Family With Li–Fraumeni Syndrome
Paduano, F., Fabiani, F., Colao, E., Trapasso, F., Perrotti, N., Barbieri, V., Baudi, F., & Iuliano, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.734809 · Cited by 5
Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer
Ghosh, T., Chen, Y., Dietz, A. C., Armstrong, G. T., Howell, R. M., Smith, S. A., Mulrooney, D. A., Turcotte, L. M., Yuan, Y., Yasui, Y., et al. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0250 · Cited by 5

Authors: Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., Caron, O., Benusiglio, P. R., Bressac-de Paillerets, B., Bonadona, V., Bonaïti-Pellié, C., Tinat, J., Baert-Desurmont, S., & Frebourg, T.
Affiliations: Inserm (FR)
Gaëlle Bougeard, Mariette Renaux-Petel, Jean-Michel Flaman, Camille Charbonnier, Pierre Fermey, Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, Institut National de la Santé et de la Recherche Médicale (Inserm) U1079, University of Rouen, Institute for Research and Innovation in Biomedicine; Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, University Hospital, Rouen; Muriel Belotti, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Curie Institute, Paris; Emilie Consolino, Laurence...
ORCID: Bougeard, Gaëlle
Flaman, Jean-Michel
Charbonnier, Camille
Brugières, Laurence
Caron, Olivier
Benusiglio, Patrick R.
Bonadona, Valérie
Tinat, Julie
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-07-20
Volume: 33
Issue: 21
Pages: 2345-2352
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.5728
OpenAlex: W2095770043
Cited by: 760
References: 42
Citations by year: 2026: 68 · 2025: 85 · 2024: 95 · 2023: 67 · 2022: 82 · 2021: 81 · 2020: 78 · 2019: 59 · 2018: 42 · 2017: 64 · 2016: 30 · 2015: 9
FWCI: 21.11
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: Li-Fraumeni syndrome, germline TP53 mutation, cancer susceptibility, multiple primary neoplasms, childhood tumors, osteosarcoma, adrenocortical carcinoma, choroid plexus carcinoma, breast cancer, soft tissue sarcoma, central nervous system tumors, loss-of-function mutations, genome rearrangement, mutation classification
MeSH terms: Adolescent, Adult, Female, France, Genetic Testing, Genotype, Humans, Male, Phenotype, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Sequence Analysis, DNA, Age of Onset, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks